Review: Traditional Chinese Medicine Compounds and Kidney Cell Senescence
This abstract reviews how Traditional Chinese Medicine compounds and formulations may act on senescent kidney cells, either by eliminating them (senolytics) or by reducing their harmful secreted signals (senomorphics). It reports potential pathways but no clinical outcomes. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract describes cellular senescence as a key driver of kidney aging and functional decline, with replicative and stress-induced forms. [1]
Strategies are grouped into senolytics, which eliminate senescent cells, and senomorphics, which mitigate detrimental paracrine effects including SASP inhibitors. [1]
Current evidence suggests several TCM-derived compounds and formulations may modulate renal senescence-related pathways, and TCM is highlighted as a multi-targeted, low-toxicity strategy. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Senescent kidney cells and aging-related kidney disease, as discussed in a review; no human participants are described.
- Summary based on
- Study abstract
- Original publication
- August 3, 2026
Senescence forms and kidney aging context
The abstract describes cellular senescence as a key driver of kidney aging and functional decline. It names two main forms: replicative senescence, mainly caused by telomere shortening, and stress-induced senescence, triggered by factors such as oxidative stress and DNA damage. Senescent cells show permanent cell cycle arrest, activation of the senescence-associated secretory phenotype (SASP) and epigenetic alterations. The text stresses that senescence is not only harmful: it also has necessary programmed roles in tissue remodeling and tumor suppression. Its chronic accumulation with age, however, is described as a major driver of organ decline.
Supporting source [1]
Senolytics, senomorphics and proposed TCM pathways
According to the abstract, specific treatments targeting senescent cells are currently lacking. It groups strategies into senolytics, which eliminate senescent cells, and senomorphics, which mitigate their detrimental paracrine effects, including SASP inhibitors. Traditional Chinese Medicine is said to have shown potential in combating aging through both mechanisms. Current evidence suggests that several TCM-derived compounds and formulations may modulate renal senescence-related pathways, including BCL-2 family-dependent apoptosis resistance, NF-κB/JAK2-STAT3/NLRP3-mediated SASP, NOX4-ROS/Nrf2 oxidative stress signaling, AMPK/mTOR/SIRT1 nutrient-sensing pathways, Klotho expression and the gut-kidney axis.
Supporting source [1]
Review scope: multi-target strategy, no clinical results
The abstract presents this as a review exploring the emerging role of TCM in renal aging. It highlights TCM's advantages as a multi-targeted, low-toxicity therapeutic strategy to mitigate aging-related kidney diseases. The text reports no human trial results, no patient numbers and no outcome data; the pathway statements are described as current evidence suggesting possible modulation. The abstract does not establish that any compound prevents, treats or reverses kidney aging in people.
Supporting source [1]
How to interpret this
This is an abstract only; the full text was not reviewed. It reports no study design, sample size, follow-up or clinical outcomes, and the pathway statements are described as suggestions from current evidence, not demonstrated human benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Li J, Li Y, Liu Y, Yang L, Ma L, Fu P. · europepmc.org · August 3, 2026